Journal of Pharmaceutical and Biomedical Analysis

Journal of Pharmaceutical and Biomedical Analysis is published by Elsevier and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Analytical Chemistry and Chromatography, Analytical Methods in Pharmaceuticals and Antibiotics Pharmacokinetics and Efficacy, together about 39.1% of its articles. (generated from OpenAlex topic counts and CAS ranking data)

This journal is an international medium directed towards the needs of academic, clinical, government and industrial analysis by publishing original research reports and critical reviews on pharmaceutical and biomedical analysis. It covers the interdisciplinary aspects of analysis in the pharmaceutical, biomedical and clinical sciences, including developments in analytical methodology, instrumentation, computation and interpretation. Submissions on novel applications focusing on drug purity and stability studies, pharmacokinetics, therapeutic monitoring, metabolic profiling; drug-related aspects of analytical biochemistry and forensic toxicology; quality assurance in the pharmaceutical industry are also welcome.Studies from areas of well established and poorly selective methods, such as UV-VIS spectrophotometry (including derivative and multi-wavelength measurements), basic electroanalytical (potentiometric, polarographic and voltammetric) methods, fluorimetry, flow-injection analysis, etc. are accepted for publication in exceptional cases only, if a unique and substantial advantage over presently known systems is demonstrated. The same applies to the assay of simple drug formulations by any kind of methods and the determination of drugs in biological samples based merely on spiked samples. Drug purity/stability studies should contain information on the structure elucidation of the impurities/degradants.Papers dealing with the analytical aspects of traditional folk medicines are acceptable if the results are expected to attract the interest of readers also outside the area of origin, i.e. they have a focus on innovative analytical approaches. Regional differences in the phytochemical content of traditional folk medicine will not be considered. Manuscripts reporting on the analysis of novel phytochemicals will only be considered if their biological activity has been previously published in an international medium. Pharmacokinetic studies of traditional folk medicine will only be considered if only the identified components have been demonstrated to be solely responsible for the pharmacological activity.Bioanalytical papers (pharmacokinetic, bioequivalence, protein and DNA binding studies) are accepted if the focus is on innovative analytical methodology. Manuscripts describing the pharmacokinetic profile of a single compound will not be considered for review. Pharmacokinetic studies will only be considered if they offer new profiles of a drug(s) and its metabolite(s) or new understandings of the mechanisms in drug disposition or response of existing drugs. Analytical studies on new investigational drugs that are currently in the preclinical phase are only acceptable if their pharmacological activity is well documented in an international medium.Human subjects research must provide ethical approval and should include the name of the approving committee and the name of the institution and reference number where approval was granted. Animal studies must be approved from their Institutions Animal Care and Use Committee or any equivalent ethics committee accompanied by the reference number. For blood sampling procedures in rodents, retro-orbital bleeding will only be considered if a minimum of 7 days is allowed between repeat sampling. Furthermore, in the evaluation of the manuscript the editors reserve the right to determine whether the animal experimental technique is appropriate.In determining the suitability of submitted articles for publication, particular scrutiny will be placed on the degree of novelty and significance of the research and the extent to which it adds to existing knowledge in pharmaceutical and biomedical analysis. In all submissions to the journal, authors must address the question of how their proposed methodology compares with previously reported methods. A substantial body of work cannot be fractionated into different shorter papers.

From the journal's Aims & Scope

Research area (LetPub): Chemistry, Analytical

Editor-in-chief Bezhan ChankvetadzePublisher website

Editorial board by country: 10 in mainland China (about 17%); most named Mainland China 10, Italy 10, Germany 6, Japan 5, United States 3 (58 members with a country) Editorial board ↗Publisher website · 2026-10-01

CAS Journal Ranking

Database indexing

SCIEScopusLetPub

International journal early-warning lists: not listed in any editionLetPub

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Impact

Impact factor

3.26LetPub · 2026-09-13

Impact factor (publisher)

3.4Publisher website · 2026-10-01

CiteScore 2026-06

6.5LetPub · 2026-09-13

CiteScore (publisher)

6.5Publisher website · 2026-10-01

SJR 2026-06

0.6LetPub · 2026-09-13

SNIP 2026-06

0.93LetPub · 2026-09-13

h-index

114LetPub · 2026-09-13

h-index

172OpenAlex · 2026-10-01

i10-index

11,879OpenAlex · 2026-10-01

2-year mean citedness

3.7OpenAlex · 2026-10-01

Self-citation rate

5.9%LetPub · 2026-09-13

Share of gold OA articles

17.93%LetPub · 2026-09-13

Volume

Articles per year

551LetPub · 2026-09-13

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Other sources

Average review time (community reports)

about 2 monthsLetPub · 2026-09-13

Average acceptance (community reports)

75%LetPub · 2026-09-13

Submission to first decision

4 daysPublisher website · 2026-10-01

First decision after review

35 daysPublisher website · 2026-10-01

Submission to acceptance

85 daysPublisher website · 2026-10-01

Acceptance to publication

2 daysPublisher website · 2026-10-01

Peer review

Single anonymous peer reviewPublisher website

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.

Publisher

Elsevier

Country or region

NETHERLANDS

Language

English

Frequency

Semimonthly

Founded

1983

ISSN

0731-7085

Electronic ISSN

1873-264X

Official links

• Journal homepage ↗LetPub
• Submission system ↗Publisher website
• Special issues ↗Publisher website